Details of the Drug Combinations

General Information of This Drug (ID: DMC56T4)

Drug Name

RAF265 DMC56T4

Synonyms

RAF265; 927880-90-8; CHIR-265; RAF 265; RAF-265; CHIR 265; RAF265 (CHIR-265); 1-Methyl-5-[[2-[5-(trifluoromethyl)-1h-imidazol-2-yl]-4-pyridinyl]oxy]-n-[4-(trifluoromethyl)phenyl]-1h-benzimidazol-2-amine; CHIR265; RAF265(CHIR-265); UNII-8O434L3768; 8O434L3768; 1-methyl-5-[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]pyridin-4-yl]oxy-N-[4-(trifluoromethyl)phenyl]benzimidazol-2-amine; 1-Methyl-5-({2-[5-(Trifluoromethyl)-1h-Imidazol-2-Yl]pyridin-4-Yl}oxy)-N-[4-(Trifluoromethyl)phenyl]-1h-Benzimidazol-2-Amine; PubChem22594

Indication

Disease Entry	ICD 11	Status	REF
Melanoma	2C30	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

16 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Birinapant + RAF265	DCMFR5G	Birinapant	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[2]
BMS-754807 + RAF265	DCWVULK	BMS-754807	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[2]
Carfilzomib + RAF265	DCT4GV7	Carfilzomib	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[2]
GDC-0980/RG7422 + RAF265	DCY8OJB	GDC-0980/RG7422	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[2]
RAF265 + Gefitinib	DCBQZ66	Gefitinib	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[2]
RAF265 + PD-0325901	DCBXCJM	PD-0325901	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[2]
RAF265 + Ym155	DCHBKBZ	Ym155	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[2]
RAF265 + Marizomib	DC0HJF3	Marizomib	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[2]
RAF265 + Chloroxine	DCCCLQG	Chloroxine	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[2]
RAF265 + Mifepristone	DCRUJU7	Mifepristone	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[2]
RAF265 + AS602868	DCCX80W	AS602868	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[2]
RAF265 + ABT-263	DC6RZUK	ABT-263	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[2]
RAF265 + IMD-0354	DCYUSXQ	IMD-0354	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[2]
RAF265 + Ruxolitinib	DCUUQK6	Ruxolitinib	Hodgkin lymphoma (Cell Line: L-1236)	[3]
RTB101 + RAF265	DC6C18S	RTB101	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[2]
Trametinib + RAF265	DCYAO0L	Trametinib	Diffuse intrinsic pontine glioma (Cell Line: SU-DIPG-XIII)	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 16 DrugCom(s)

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5674).
2	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
3	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.